These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31898869)

  • 21. Matched unrelated bone marrow transplantation without splenectomy for a child with Gaucher disease caused by homozygosity of the L444P mutation, who also suffered from schizencephaly.
    Chen RL; Hou JW; Chang PY; Tsai FJ; Wang PJ
    J Pediatr Hematol Oncol; 2007 Jan; 29(1):57-9. PubMed ID: 17230068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.
    Zhong W; Li D; Fei Y; Hong P
    Acta Neurol Belg; 2024 Aug; 124(4):1213-1223. PubMed ID: 38413480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
    Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical phenotype and genotype of Gaucher disease in 14 children].
    Sun XY; Xue Y; Wang YP; Huang J; Lin RF; Kang MY; Fang YJ
    Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):527-532. PubMed ID: 35658357
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
    Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corneal manifestations and in vivo confocal microscopy of Gaucher disease.
    Geens S; Kestelyn P; Claerhout I
    Cornea; 2013 Jul; 32(7):e169-72. PubMed ID: 23635853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical management of Type 2 Gaucher disease.
    Weiss K; Gonzalez A; Lopez G; Pedoeim L; Groden C; Sidransky E
    Mol Genet Metab; 2015 Feb; 114(2):110-122. PubMed ID: 25435509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypes and phenotypes in 20 Chinese patients with type 2 Gaucher disease.
    Kang L; Wang Y; Gao X; Qiu W; Ye J; Han L; Gu X; Zhang H
    Brain Dev; 2018 Nov; 40(10):876-883. PubMed ID: 29934114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gaucher disease.
    Guggenbuhl P; Grosbois B; Chalès G
    Joint Bone Spine; 2008 Mar; 75(2):116-24. PubMed ID: 17996473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perinatal lethal phenotype with generalized ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]/P182L genotype: effect of the E326K change in neonatal and classic forms of the disease.
    Chabás A; Gort L; Díaz-Font A; Montfort M; Santamaría R; Cidrás M; Grinberg D; Vilageliu L
    Blood Cells Mol Dis; 2005; 35(2):253-8. PubMed ID: 15967693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons learned from the development of enzyme therapy for Gaucher disease.
    Barranger JA; O'Rourke E
    J Inherit Metab Dis; 2001; 24 Suppl 2():89-96; discussion 87-8. PubMed ID: 11758684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type I Gaucher's disease with homozygous R463C mutation without neurological involvement.
    Bolaman Z; Kadikoylu G; Levi E; Barutca S; Temucin K
    Haematologia (Budap); 2002; 32(4):487-93. PubMed ID: 12803123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocerebrosidase mutations among Chinese neuronopathic and non-neuronopathic Gaucher disease patients.
    Choy FY; Wong K; Shi HP
    Am J Med Genet; 1999 Jun; 84(5):484-6. PubMed ID: 10360404
    [No Abstract]   [Full Text] [Related]  

  • 35. [Gaucher disease: clinical, genetic and therapeutic aspects].
    Germain DP
    Pathol Biol (Paris); 2004 Jul; 52(6):343-50. PubMed ID: 15261378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gaucher disease: studies of phenotype, molecular diagnosis and treatment.
    Rice EO; Mifflin TE; Sakallah S; Lee RE; Sansieri CA; Barranger JA
    Clin Genet; 1996 Mar; 49(3):111-8. PubMed ID: 8737974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gaucher disease type 3c: New patients with unique presentations and review of the literature.
    Kurolap A; Del Toro M; Spiegel R; Gutstein A; Shafir G; Cohen IJ; Barrabés JA; Feldman HB
    Mol Genet Metab; 2019 Jun; 127(2):138-146. PubMed ID: 31130326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Divergent phenotypes in Gaucher disease implicate the role of modifiers.
    Goker-Alpan O; Hruska KS; Orvisky E; Kishnani PS; Stubblefield BK; Schiffmann R; Sidransky E
    J Med Genet; 2005 Jun; 42(6):e37. PubMed ID: 15937077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease.
    Sanders A; Hemmelgarn H; Melrose HL; Hein L; Fuller M; Clarke LA
    Blood Cells Mol Dis; 2013 Aug; 51(2):109-15. PubMed ID: 23642305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients.
    Kraoua I; Sedel F; Caillaud C; Froissart R; Stirnemann J; Chaurand G; Flodrops H; Tari S; Gourfinkel-An I; Mathieu S; Belmatoug N; Billette de Villemeur T; Mignot C
    Brain Dev; 2011 Feb; 33(2):131-9. PubMed ID: 20307947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.